GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce lipid accumulation in peripheral tissues, attenuating atherosclerosis and hepatic steatosis in preclinical studies. We examined whether GLP-1R activation decreases atherosclerosis progression in high-fat diet-fed male ApoE(-/-) mice after administration of streptozotocin and treatment with the long-acting GLP-1R agonist taspoglutide administered once monthly vs. metformin in the drinking water for 12 wk. Taspoglutide did not reduce plaque area or lipid content in the aortic arch or abdominal aorta, and no significant change in aortic macrophage accumulation was detected after taspoglutide or metformin. In contrast, hepatic triglyceride levels were significantly reduced in livers from taspoglutide-treated mice. Both peripheral and intracerebroventricular administration of exendin-4 rapidly decreased plasma triglyceride levels in fasted mice, and taspoglutide therapy in ApoE(-/-) mice modulated the expression of hepatic genes controlling fatty acid uptake and oxidation. We were unable to detect expression of the entire Glp1r coding sequence in macrophages isolated from ApoE(-/-), C57BL/6, and IL10(-/-) mice. Similarly, Glp1r mRNA transcripts were not detected in RNA from isolated murine hepatocytes. Using Western blotting and tissue extracts from Glp1r(+/+) and Glp1r(-/-) mice, and cells transfected with a tagged murine GLP-1R cDNA, we could not validate the sensitivity and specificity of three different GLP-1R antisera commonly used for the detection of GLP-1R protein. Taken together, these findings illustrate divergent actions of GLP-1R agonists on atherosclerosis progression and accumulation of ectopic lipid in ApoE(-/-) mice and highlight the importance of indirect GLP-1R actions for the control of hepatic lipid accumulation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glp1r expression is undetectable by quantitative PCR in peritoneal or adipose tissue macrophages (37), although Lyz2-Cre–driven deletion of Glp1r (Glp1rLyz2–/–) abolishes expression in bone marrow–derived macrophages (38).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [37]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 2×
“Histological sections were scored for hepatic lobular inflammation, ballooning, apoptosis, Kupffer cells, fibrosis, and steatosis according to guidelines set by the Pathology Committee of the NASH (nonalcoholic steatohepatitis) Clinical Research Network (25) in a blinded manner by a trained pathologist (C.”
Metabolism of Isolated Fat Cells
Rodbell, M. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51687-2 · Cited by 4,427
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Two of the relatively newer classes, glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, exert their glucose-lowering actions predominantly through activation of the GLP-1R (2).”
Self-citationMETABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS.
Rodbell, M. (1964) · PubMed · Cited by 1,387
Insulin Resistance, Hyperglycemia, and Atherosclerosis
Bornfeldt, K. E., & Tabas, I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.015 · Cited by 995 · cited 3×
“Although hyperglycemia and insulin resistance substantially accelerate the development of clinical and experimental atherosclerosis (11), whether sustained activationofGLP-1Rsignalingmightattenuate thedevelopment of atherosclerosis in the setting of insulin resistance, impairment of -cell function, and hyperglycemia r…”
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 6×
“D PBO (14) D Met PBO (15) D TASPO (15) * * ** ***”
InfluentialSelf-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 2×
“In contrast, other investigators have failed to detect mRNA transcripts encoding a full-length Glp1r in human, rat, or mouse liver (17, 37, 47-49), and we previously reported the absence of cAMP accumulation in response to GLP-1 or exendin-4 in isolated murine hepatocytes (17).”
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · cited 1×
“ocytes and exert direct effects in the cardiovascular system (3).”
Self-citation
Cited by
Items 301–346 of 346
Yu, W., Liu, Y., Le, S., Xiao, Y., Chen, X., Wang, J., & Gao, F. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70174 · Cited by 4
Barbosa, I. A., Santos, E. M., Paraíso, A. F., Chagas, P. V. F., Oliveira, L. P., Andrade, J. M. O., Farias, L. C., de Carvalho, B. M. A., de Paula, A. M. B., Guimarães, A. L. S., et al. (2019) · Meta Gene · doi:10.1016/j.mgene.2019.100553 · Cited by 2
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., Koehler, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522509 · Cited by 2
Self-citationDear, A. E. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6465-x · Cited by 1
“Whilst a mounting body of credible scientific evidence supports a potential role for the incretin system in general and GLP-1R agonists including liraglutide specifically in the modulation of the atherogenesis process the presence of recent, convincing however discordant publications forces a reevaluation of the under…”
BackgroundZhang, S.-J., Xu, K., Zhu, F., Chen, J.-G., Zhang, Y., Teng, Y.-Q., & Shen, F.-F. (2026) · Physiological Research · doi:10.33549/physiolres.935711 · Cited by 2
“…is an adipokine that enhances hepatic lipid oxidation and reduces inflammation by activating adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2), which in turn regulate the AMP-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor α (PPARα) pathway [20].”
Incretin-based therapies for the failing heart
Ussher, J. R., & Campbell, J. E. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000086 · Cited by 1
Self-citationTian, Q., Liu, Y., Yuan, P., Liu, J., Li, H., Han, X., Pan, C., Wu, Y., Zhou, Z., Liu, S., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134328 · Cited by 1
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Association of dipeptidyl peptidase-4 with Alzheimer's disease: A new therapeutic prospect
Wang, X., Chen, L., Li, W., He, Z., & Hai-ying, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241304673 · Cited by 1
Kheder, M. H. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.122879 · Cited by 1
GLP-1 receptor – Do we really know what we’re looking at?
Homolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., & Šalković‐Petrišić, M. (2021) · Acta Histochemica · doi:10.1016/j.acthis.2021.151732 · Cited by 1
GLP-1R activation is a key pathway to alleviate the metabolic disorder in L02 cellsPreprint
Tian, Q. J., Liu, Y., Liu, J., Yuan, P., Li, H., Han, X.-F., Pan, C., Duan, S., & Xia, K. (2020) · doi:10.21203/rs.3.rs-29811/v1 · Cited by 1
“Naim et al. showed that GLP-1R mRNA transcription could not be detected from mouse hepatocytes and the indirect GLP-1R actions for the regulation of hepatic lipid accumulation(Naim et al., 2013).”
BackgroundNjei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Ameyaw, P. A., Njei, L., & Boateng, S. (2024) · doi:10.22541/au.171585503.34303032/v1 · Cited by 1
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Pleiotropic Effects of an Incretin Hormone
Oh, S. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.120
[History of medicine. Souvenirs and the tales of 2 anesthetists from their beginnings in Liège].
Klutz, A., & Piret, R. (1990) · PubMed
Obesity alters global response to ischemia and GLP-1 agonism
Sassoon, D. (2016) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2016
The potential for renoprotection with incretin-based
Higashijima, Y., Wada, T., & Nangaku, M. (2014)
The Role of Transcription Factor 7-Like 2 in Hepatic Glucose Metabolism
Ip, W. (2014) · TSpace (University of Toronto)
Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes
Cusi, K. J. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_4
The Cardiac Glucagonlike Peptide-1 Receptor: Whither Art Thou?
Brubaker, P. L. (2018) · Endocrinology · doi:10.1210/en.2018-00186
Generation and use of new tools for the characterisation of gut hormone receptors
Biggs, E. K. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.37487
Farr, S. (2017) · TSpace (University of Toronto)
Gastrointestinal tract and type 2 diabetes. Physiological and pathophysiological aspects
Okhunov, A. O., Маърупов, И. О. У., & Razzakov, S. R. (2020) · doi:10.18411/lj-03-2020-08
Taher, J. (2017) · TSpace (University of Toronto) · Cited by 1
Tian, Q. J., Liu, Y., Yuan, P., Liu, J., Li, H., Han, X., Pan, C., Duan, S., & Xia, K. (2020) · doi:10.21203/rs.3.rs-29811/v2
Advances in Biological and Clinical Research of GLP-1 Receptor Agonists
李, 鑫. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124430
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Al‐Sabah, S., Jamal, M. H., Al‐Khaledi, G., Dsouza, C. L., AlOtaibi, F., Al-Ali, W., Cherian, P., Al‐Khairi, I., Ali, H., Abu‐Farha, M., et al. (2023) · Medical Principles and Practice · doi:10.1159/000533746 · Cited by 1
Demidova, T. Y., Titova, V. V., & Izmaylova, M. Y. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.10.202425
Mermet, M., Denom, J., Mieczkowska, A., Biggs, E. K., Gribble, F. M., Reimann, F. M., Magnan, C., Cruciani‐Guglielmacci, C., & Mabilleau, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.05.616809
Advancing Understanding of Cardiovascular Risk in CKD
Sridhar, V. S., & Odutayo, A. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000606
Zhang, Z., Liu, S., Xian, J., Zhang, Y., Zhang, C., Wang, Z., Deng, H., Feng, J., & Yao, L. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26154
“…of fatty acids and glucose to the heart [11], suppressing inflammation by regulating the expression of inflammatory genes in peripheral blood mononuclear cells [101], and reducing body weight by regulating adipocyte development and stimulating thermogenesis in brown adipose tissue (BAT) [ 100,102].”
Bzoma, M., Bochenek, H., Kamiński, P., Czerepak, I., Gugulska, J., Bielicka, A., Szwarc, T., Kałwik, M., Niewczas, K., & Brzozowska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3493
Guo, T., Yan, W., Cui, X., Liu, N., Wei, X., Sun, Y., Fan, K., Liu, J., Zhu, Y., Wang, Z., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26620690
A comprehensive review of GLP-1 and aerobic training in cardiovascular disease management
Kordi, N., Kheirandish, R., Akraminia, P., Jung, F., & Karami, S. (2025) · Clinical Hemorheology and Microcirculation · doi:10.1177/13860291251414840
“49 In opposition, a study revealed that mice with mild hyperglycemia on a high-fat diet did not experience a reduction in aortic arch fat content, atherosclerotic plaques, or macrophage accumulation after 12 weeks of treatment with a GLP-1 receptor agonist.”
Kristensen, J. B., Nøhr-Meldgaard, J., Pors, S. E., Norlin, J., Veidal, S. S., Bendtsen, K. M., Niss, K., Andersen, M. W., Harder, L. M., Dalhoff, M. T., et al. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00011.2026 · Cited by 1
Wallentowitz, L., García, M. G., Atorrasagasti, C., Harms, C., Huhn, E. A., Roser, P., Verlohren, S., Giesen, E. M., & Blois, S. M. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10053-6 · Cited by 4
Wu, H., Zhang, Z., Ye, T., Chen, J.-N., Tung, T., & Zhu, J. F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1783429
Cai, D., Nguyen, H., Zhang, Y., Sharma, S. T. B. A. S. L. A. S. J. S. S. T. B. A. S. L. A. S. J., Schilke, A., Raychouni, R., Heredia, E., Abel‐Santos, E., Firestine, S. M., & Liu, W. T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.11.731657
Khalifa, A. S., Ibrahim, A., Khalid, S., Abdelfattah, A. M., Bakkar, N. Z., Elrewiny, M. A., & El-Yazbi, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44173-8.00021-8
Glucagon-like peptide-1 regulates lipid metabolism through actions in the gut and liver
Lewis, G. F., Feng, J. N., & Jin, T. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100023
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Kang, Y. W. (2026) · Kosin Medical Journal · doi:10.7180/kmj.26.193
Metadata
- Authors
- Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- St. Michael's Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 154
- Issue
- 1
- Pages
- 127-139
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1992116679
- Cited by
- 346
- References
- 53
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 23 · 2022: 23 · 2021: 21 · 2020: 24 · 2019: 23 · 2018: 27 · 2017: 24 · 2016: 26 · 2015: 32 · 2014: 38 · 2013: 32
- FWCI
- 26.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- GLP-1 receptor, exendin-4, atherosclerosis, hepatic lipid accumulation, hepatic steatosis, ApoE-deficient mice, streptozotocin-induced diabetes, metformin, aortic plaque, hepatic triglycerides, fatty acid uptake, fatty acid oxidation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Apolipoproteins E, Body Composition, Glucose Tolerance Test, Liver, Macrophages, Male, Peptides, Blotting, Western, Interleukin-10, Receptors, Glucagon, Mice, Knockout, Hepatocytes, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.